title: ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.
abstract: Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of commonly fatal malignancies of immunocompromised individuals, including primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS). A hallmark of all herpesviruses is their biphasic life cycle-viral latency and the productive lytic cycle-and it is well established that reactivation of the KSHV lytic cycle is associated with KS pathogenesis. Therefore, a thorough appreciation of the mechanisms that govern reactivation is required to better understand disease progression. The viral protein replication and transcription activator (RTA) is the KSHV lytic switch protein due to its ability to drive the expression of various lytic genes, leading to reactivation of the entire lytic cycle. While the mechanisms for activating lytic gene expression have received much attention, how RTA impacts cellular function is less well understood. To address this, we developed a cell line with doxycycline-inducible RTA expression and applied stable isotope labeling of amino acids in cell culture (SILAC)-based quantitative proteomics. Using this methodology, we have identified a novel cellular protein (AT-rich interacting domain containing 3B [ARID3B]) whose expression was enhanced by RTA and that relocalized to replication compartments upon lytic reactivation. We also show that small interfering RNA (siRNA) knockdown or overexpression of ARID3B led to an enhancement or inhibition of lytic reactivation, respectively. Furthermore, DNA affinity and chromatin immunoprecipitation assays demonstrated that ARID3B specifically interacts with A/T-rich elements in the KSHV origin of lytic replication (oriLyt), and this was dependent on lytic cycle reactivation. Therefore, we have identified a novel cellular protein whose expression is enhanced by KSHV RTA with the ability to inhibit KSHV reactivation.
  
  
  
  Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of fatal malignancies of immunocompromised individuals, including Kaposi's sarcoma (KS). Herpesviruses are able to establish a latent infection, in which they escape immune detection by restricting viral gene expression. Importantly, however, reactivation of productive viral replication (the lytic cycle) is necessary for the pathogenesis of KS. Therefore, it is important that we comprehensively understand the mechanisms that govern lytic reactivation, to better understand disease progression. In this study, we have identified a novel cellular protein (AT-rich interacting domain protein 3B [ARID3B]) that we show is able to temper lytic reactivation. We showed that the master lytic switch protein, RTA, enhanced ARID3B levels, which then interacted with viral DNA in a lytic cycle-dependent manner. Therefore, we have added a new factor to the list of cellular proteins that regulate the KSHV lytic cycle, which has implications for our understanding of KSHV biology.
authors: School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
authors: Jennifer J
authors: JJ
authors: Wood
authors: Centre for Skin Sciences, University of Bradford, Bradford, United Kingdom.
authors: James R
authors: JR
authors: Boyne
authors: Biomedical Sciences Research Complex, University of St. Andrews, St. Andrews, United Kingdom.
authors: Christina
authors: C
authors: Paulus
authors: School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom The Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
authors: Brian R
authors: BR
authors: Jackson
authors: Biomedical Sciences Research Complex, University of St. Andrews, St. Andrews, United Kingdom.
authors: Michael M
authors: MM
authors: Nevels
authors: School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom The Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom a.whitehouse@leeds.ac.uk djh25@st-andrews.ac.uk.
authors: Adrian
authors: A
authors: Whitehouse
authors: Biomedical Sciences Research Complex, University of St. Andrews, St. Andrews, United Kingdom a.whitehouse@leeds.ac.uk djh25@st-andrews.ac.uk.
authors: David J
authors: 0000-0002-0090-5710
authors: DJ
authors: Hughes
mesh_terms: D045744:Cell Line, Tumor; D047369:Chromatin Immunoprecipitation / Q000379:methods; D004261:DNA Replication / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D015967:Gene Expression Regulation, Viral / Q000235:genetics; D019288:Herpesvirus 8, Human / Q000235:genetics*; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics; D054685:Lymphoma, Primary Effusion / Q000235:genetics / Q000821:virology; D034741:RNA, Small Interfering / Q000235:genetics; D012514:Sarcoma, Kaposi / Q000821:virology*; D015534:Trans-Activators / Q000235:genetics; D014764:Viral Proteins / Q000235:genetics*; D014775:Virus Activation / Q000235:genetics; D017735:Virus Latency / Q000235:genetics; D014779:Virus Replication / Q000235:genetics
chemical_list: C120893:ARID3B protein, human; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D017874:Immediate-Early Proteins; D034741:RNA, Small Interfering; D015534:Trans-Activators; D014764:Viral Proteins